In This Article:
The Australian stock market has shown resilience with the ASX200 rising by 1% to 8,491 points, as easing tariff concerns and a stronger Aussie dollar support investor sentiment. In such a climate, identifying stocks that combine affordability with growth potential is key. While the term "penny stocks" might seem outdated, these smaller or newer companies can still offer intriguing opportunities for investors seeking value beyond the mainstream market leaders.
Top 10 Penny Stocks In Australia
Name | Share Price | Market Cap | Financial Health Rating |
Embark Early Education (ASX:EVO) | A$0.78 | A$143.12M | ★★★★☆☆ |
LaserBond (ASX:LBL) | A$0.57 | A$66.82M | ★★★★★★ |
Austin Engineering (ASX:ANG) | A$0.505 | A$313.17M | ★★★★★☆ |
Helloworld Travel (ASX:HLO) | A$2.02 | A$328.89M | ★★★★★★ |
GTN (ASX:GTN) | A$0.5425 | A$106.53M | ★★★★★★ |
SHAPE Australia (ASX:SHA) | A$3.00 | A$248.73M | ★★★★★★ |
MaxiPARTS (ASX:MXI) | A$1.90 | A$105.1M | ★★★★★★ |
IVE Group (ASX:IGL) | A$2.18 | A$337.66M | ★★★★☆☆ |
SKS Technologies Group (ASX:SKS) | A$1.59 | A$243.19M | ★★★★★★ |
Centrepoint Alliance (ASX:CAF) | A$0.315 | A$62.65M | ★★★★★☆ |
Click here to see the full list of 1,031 stocks from our ASX Penny Stocks screener.
Let's review some notable picks from our screened stocks.
Cogstate
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Cogstate Limited is a neuroscience technology company focused on developing and commercializing digital brain health assessments for academic and industry-sponsored research, with a market cap of A$202.16 million.
Operations: The company's revenue is derived from two main segments: Healthcare (including Sport) generating $3.99 million and Clinical Trials (including Precision Recruitment Tool & Research) contributing $39.44 million.
Market Cap: A$202.16M
Cogstate Limited, with a market cap of A$202.16 million, has shown robust financial health and growth potential in the penny stock segment. The company reported significant earnings growth of 52.8% over the past year, surpassing its five-year average of 41.9% annually, and maintains high-quality earnings with a net profit margin improvement to 12.5%. Its short-term assets exceed both short-term and long-term liabilities significantly, indicating strong liquidity management. Cogstate's debt level is minimal compared to its cash reserves, ensuring interest payments are well-covered by EBIT (120.5x coverage), reflecting sound financial stability for investors considering penny stocks in Australia.
-
Dive into the specifics of Cogstate here with our thorough balance sheet health report.
-
Understand Cogstate's earnings outlook by examining our growth report.
Magontec
Simply Wall St Financial Health Rating: ★★★★★☆